Since chronic kidney disease ( CKD ) is common in these patients , we conducted a post-hoc analysis of 2 replicate phase 3 trials and the subsequent open-label extension study to determine the effects of pegloticase on renal function in patients with CKD stages 3 and 4 , as well as the effects of renal dysfunction on pegloticase efficacy and safety .